Moreover, our in vivo study using a HER2-overexpressing PDTX model demonstrated that combining samfenet with an injection of NK92-CD16 cells significantly reduced tumor size compared with monotherapy, confirming the NK cell-mediated ADCC effect. This evidence concerns the gene ERBB2 and neoplasm.